Thanks @GCInvestor . Let's hope that publication can be expedited and brought forward from Q2 to Q1. FDA approval is a critical gateway to large-scale commercialisation for Neurotech.
But I'm not getting my hopes up too much. Commercialisation of the product will not be a priority for the Carrick Institute. They will be far more concerned about credibility and rigour, so they absolutely will not rush through preparation of the paper.
Our best hope is that the journal's editorial team will decide that the news is sufficiently important to warrant publication ahead of earlier submissions.
NTI Price at posting:
22.5¢ Sentiment: Hold Disclosure: Held
